Tricida is in a liquidation posture, with the debtor’s operative path reflected in a third amended chapter 11 liquidation plan rather than a going-concern reorganization. The case began on January 11, 2023, after the company’s lead drug candidate, veverimer, suffered a clinical-trial failure in October 2022 when the VALOR-CKD trial did not meet its primary endpoint, cutting off Tricida’s practical ability to raise new capital and continue R&D; by the petition date, the debtor also faced a large unsecured overhang, including estimated trade and other general unsecured claims in excess of $140 million, as described in the Perkins first-day declarationDkt. 2.
The filing followed prepetition cost cuts, a reduction in headcount, engagement of SierraConstellation Partners as financial advisor, and negotiations with convertible noteholders that produced a restructuring support agreement backed by more than 80% of noteholders. That agreement framed an expedited chapter 11 process built around sale procedures, a liquidation plan, a liquidating trust for residual assets, and creditor recoveries under a milestone-driven timetable, with first-day relief focused on preserving basic operations while the debtor pursued that endgame through the chapter 11 petitionDkt. 1 and supporting first-day papers.
The plan trajectory moved quickly: Tricida filed a disclosure statement one week after the petition date, setting out a liquidation structure for the debtor’s remaining assets and claim treatment framework in the disclosure statement for the liquidation planDkt. 72. The current restructuring posture is therefore a wind-down and claims-resolution case, with the latest cited plan source being the , which identifies Tricida as plan sponsor, provides for eight classes, and confirms that the debtor’s path is liquidation rather than emergence as an operating business.
